530 related articles for article (PubMed ID: 9445406)
1. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
McLaughlin VV; Genthner DE; Panella MM; Rich S
N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
[TBL] [Abstract][Full Text] [Related]
2. Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin).
Klings ES; Hill NS; Ieong MH; Simms RW; Korn JH; Farber HW
Arthritis Rheum; 1999 Dec; 42(12):2638-45. PubMed ID: 10616012
[TBL] [Abstract][Full Text] [Related]
3. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
[TBL] [Abstract][Full Text] [Related]
4. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
Barst RJ; Rubin LJ; Long WA; McGoon MD; Rich S; Badesch DB; Groves BM; Tapson VF; Bourge RC; Brundage BH; Koerner SK; Langleben D; Keller CA; Murali S; Uretsky BF; Clayton LM; Jöbsis MM; Blackburn SD; Shortino D; Crow JW;
N Engl J Med; 1996 Feb; 334(5):296-301. PubMed ID: 8532025
[TBL] [Abstract][Full Text] [Related]
5. [Short- and long-term effects of the new oral prostacyclin analogue, beraprost sodium, in patients with severe pulmonary hypertension].
Saji T; Ozawa Y; Nakayama T; Matsuura H; Hashiguchi R; Matsuo N; Muto H; Yamazaki J; Morishita T; Saito T
J Cardiol; 1996 Apr; 27(4):197-205. PubMed ID: 8642506
[TBL] [Abstract][Full Text] [Related]
6. [Effects of long-term treatment with prostacyclin on plasma adrenomedullin in patients with primary pulmonary hypertension].
Nakayama T; Ishikita T; Matsuura H; Saji T
J Cardiol; 2001 Nov; 38(5):263-71. PubMed ID: 11729726
[TBL] [Abstract][Full Text] [Related]
7. Sustained improvement of performance and haemodynamics with long-term aerosolised prostacyclin therapy in severe pulmonary hypertension.
Stricker H; Domenighetti G; Fiori G; Mombelli G
Schweiz Med Wochenschr; 1999 Jun; 129(24):923-7. PubMed ID: 10413827
[TBL] [Abstract][Full Text] [Related]
8. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension.
Krowka MJ; Frantz RP; McGoon MD; Severson C; Plevak DJ; Wiesner RH
Hepatology; 1999 Sep; 30(3):641-8. PubMed ID: 10462369
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue.
Hoeper MM; Schwarze M; Ehlerding S; Adler-Schuermeyer A; Spiekerkoetter E; Niedermeyer J; Hamm M; Fabel H
N Engl J Med; 2000 Jun; 342(25):1866-70. PubMed ID: 10861321
[TBL] [Abstract][Full Text] [Related]
10. Does Sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung and cardiac disease?
Madden BP; Sheth A; Wilde M; Ong YE
Vascul Pharmacol; 2007; 47(2-3):184-8. PubMed ID: 17627899
[TBL] [Abstract][Full Text] [Related]
11. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment.
Fisher KA; Serlin DM; Wilson KC; Walter RE; Berman JS; Farber HW
Chest; 2006 Nov; 130(5):1481-8. PubMed ID: 17099027
[TBL] [Abstract][Full Text] [Related]
12. Continuous intravenous epoprostenol in pulmonary hypertension: the Israel experience.
Bendayan D; Fink G; Aravot D; Ygla M; Bendov I; Bliden L; Nir A; Kramer MR
Isr Med Assoc J; 2002 Apr; 4(4):255-8. PubMed ID: 12001697
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous findings in patients with pulmonary arterial hypertension receiving long-term epoprostenol therapy.
Myers SA; Ahearn GS; Angelica Selim M; Tapson VF
J Am Acad Dermatol; 2004 Jul; 51(1):98-102. PubMed ID: 15243533
[TBL] [Abstract][Full Text] [Related]
14. Comparison between two drugs on the hemodynamic evaluation of pulmonary hypertension prior to heart transplantation.
Mogollón Jiménez MV; Escoresca Ortega AM; Hinojosa Pérez R; Lage Gallé E; Herruzo Avilés A; Sobrino Márquez M; Frutos López M; Romero Rodríguez N; Pérez de la Yglesia R; Martínez Martínez A
Transplant Proc; 2008 Nov; 40(9):3009-11. PubMed ID: 19010174
[TBL] [Abstract][Full Text] [Related]
15. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation.
Conte JV; Gaine SP; Orens JB; Harris T; Rubin LJ
J Heart Lung Transplant; 1998 Jul; 17(7):679-85. PubMed ID: 9703232
[TBL] [Abstract][Full Text] [Related]
16. Epoprostenol treatment in children with severe pulmonary hypertension.
Lammers AE; Hislop AA; Flynn Y; Haworth SG
Heart; 2007 Jun; 93(6):739-43. PubMed ID: 17065181
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol.
Fix OK; Bass NM; De Marco T; Merriman RB
Liver Transpl; 2007 Jun; 13(6):875-85. PubMed ID: 17539008
[TBL] [Abstract][Full Text] [Related]
18. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension.
Kähler CM; Graziadei I; Wiedermann CJ; Kneussl MP; Vogel W
Wien Klin Wochenschr; 2000 Jul; 112(14):637-40. PubMed ID: 11008327
[TBL] [Abstract][Full Text] [Related]
19. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside.
Kieler-Jensen N; Lundin S; Ricksten SE
J Heart Lung Transplant; 1995; 14(3):436-43. PubMed ID: 7654728
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary hypertension--beyond vasodilator therapy.
Fishman AP
N Engl J Med; 1998 Jan; 338(5):321-2. PubMed ID: 9445414
[No Abstract] [Full Text] [Related]
[Next] [New Search]
